Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04447495 |
| Other study ID # |
20-001 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
July 1, 2020 |
| Est. completion date |
December 31, 2020 |
Study information
| Verified date |
December 2021 |
| Source |
Medical College of Wisconsin |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
This study will evaluate the feasibility of self-sampling with the iAMP® COVID-19 Detection
Kit (Atila BioSystems, Mountain View, CA), a new, low-cost SARS-CoV-2 test that does not
require RNA extraction. The investigators will compare the sensitivity and specificity of the
iAMP® assay on self-sampled mid-turbinate, anterior nares, and saliva swabs against the gold
standard, a nucleic acid amplification testing assay on a clinician-collected nasopharyngeal
swab.
Description:
3.1.1 Study population: The investigators will enroll patients within a larger clinical
validation study of the iAMP® test against the gold standard (the CDC-recommended test) until
we have prospectively collected a total of 100 positive cases. Current positivity in the
region is approximately 20%, therefore, approximately 500 samples will be needed. Inclusion
criteria are as follows: Patients older than 18 presenting for COVID-19 testing, able to
tolerate nasopharyngeal swabs, and able to follow instructions for self-collection. Exclusion
criteria are as follows: unable or unwilling to provide informed consent and/or reliable
contact information.
3.1.2 Clinical visit: Symptomatic patients will be approached by a study provider wearing
PPE. The study will be explained and if the patient agrees, they will be consented. Patients
will be allowed to consent for just the two nasopharyngeal swabs or for all five swabs. After
consent, each patient will undergo testing with simultaneous placement of two nasopharyngeal
swabs by a clinician for the large-scale clinical validation. One will be stored dry in a
tube and one will be placed in viral collection medium. Patients who consent to the
self-sampling study will be taken to a private area for collection of three different
samples. After receiving written instructions and watching a short instructional video, the
mid-turbinate sample will be collected by the patient under the supervision of a clinician.
The clinician will then leave and the patient will self-collect samples from the anterior
nares and saliva. All samples will be stored dry. When the patient returns the samples to the
research coordinator, they will be asked about any side effects or adverse events from the
mid-turbinate sample.
3.1.3 Laboratory testing: A dry swab will be collected from two of the three iAMP®
self-sample sites - mid-turbinate and anterior nares - and placed into a vial with the
proprietary buffer (hereafter referred to as Sample Buffer A). For saliva, a sterile
collection cup will be used for the sample collection, and Sample Buffer A will be added
directly to the sterile collection cup. Each of the three samples with the added Sample
Buffer A will incubate at room temperature for 15 minutes. A proprietary multiplex mixture
(master mix) will be prepared in a test tube and 10 microliters of the sample from the vial
(mid turbinate and nares) or cup (saliva) will be added to the test tube. The test tube will
then be placed into the RT-PCR machine and run to completion of the assay. The assay will be
resulted as either positive, negative or invalid (test to be repeated) and the result
compared to the anonymized result of the nasopharyngeal test run with the CDC recommended
NAAT assay.
Instructions for subjects on how to correctly collect the swabs from each site. [Cotton swabs
should be flocked and tapered].
Mid-turbinate:
- Wash and dry hands thoroughly
- Take a sterile cotton swab and hold it by the stem in your dominant hand
- Open the empty iAMP collection vial and hold it in the other hand
- Tilt your head back so chin is roughly parallel to ground (~70º)
- Insert the cotton swab to the mark on the stem (one inch, or ~2 cm) and rotate the
cotton swab completely (360º) 3 times.
- Remove the swab and without touching the cotton tip, repeat the process on the other
side with the same cotton swab
- Remove the swab from the nose, do not touch the cotton tip, and place the swab, cotton
tip first, into the vial
- Break off the upper stem of the cotton swab
- Replace the cap onto the vial, closing it securely
- Give the closed vial to the research personnel
Anterior nares:
- Wash and dry hands thoroughly
- Take a sterile cotton swab and hold it by the stem in your dominant hand
- Open the empty iAMP® collection vial and hold it in the other hand
- Insert the cotton swab into one nostril just until the cotton tip is no longer visible
(~0.5 inches, or 1 cm)
- Rotate it inside the nose completely (360º) 3 times and leave it in place for 10-15
seconds
- Remove the swab and without touching the cotton tip, repeat the process in the other
nostril, again inserting the cotton swab only until the cotton tip is no longer visible,
rotating it 3 times and leaving it in place for 10-15 seconds
- Remove the swab, do not touch the cotton tip, and place the swab, cotton tip first, into
the vial
- Break off the upper stem of the cotton swab
- Replace the cap onto the vial, closing it securely
- Give the closed vial to the research personnel
Saliva:
- Do not eat, drink, smoke or chew gum within 30 minutes of the collection
- Take a sterile urine cup and spit repeatedly into it until there is 2-3 milliliters of
liquid (excluding bubbles). See image below for example of amount of saliva needed
- Keep inside of cup sterile by NOT placing anything (fingers, objects, etc) into the cup
- Once adequate amount of saliva collected, place the cap onto the top of the cup and
close it securely
- Give closed cup to research personnel
3.1.4 Statistical justification Assuming 20% of specimens tested with the NAAT assay will be
COVID-19 positive, a study of 500 consecutive specimens will yield 100 COVID-19 cases
detected by the NAAT assay. This study will be able to estimate the 95% confidence interval
(CI) for sensitivity and specificity indicated in the table below for true sensitivity and
specificity ranging from 50% to 95%. The precision improves the farther the sensitivity and
specificity differ from 50%.
Table 1: 95% confidence intervals for detecting sensitivity and specificity True Sensitivity
Sensitivity 95% CI True Specificity Specificity 95% CI 50% 39.8% - 60.2% 50% 45.0% - 55.0%
70% 60.0% - 78.8% 70% 65.2% - 74.5% 90% 82.4% - 95.1% 90% 86.6% - 92.8% 95% 88.7% - 98.4% 95%
92.3% - 96.9%
3.1.5 Risks/Safety The only risk of this study is the additional exposure of the laboratory
personnel performing the assay. All laboratorians involved are trained in handling infectious
agents such as COVID-19. All standard precautions will be used for the handling of the
specimens including aliquoting samples in a Biosafety hood and the use of Personal Protective
Equipment. Patient confidentiality will be assured by the anonymizing of patient samples as
previously approved by the MCW IRB.
3.1.6 Analysis. Sensitivity and specificity will be estimated for each iAMP® test as well as
corresponding 95% exact confidence intervals using the NAAT assay as the reference standard.
3.1.7 Potential Clinical Limitations
1. Alternative anatomic sites will have lower sensitivity than nasopharyngeal swabs. It is
possible that the self-collected swabs will have significantly lower sensitivity than
nasopharyngeal swabs. This is unlikely to be the case because viral load with this novel
virus is very high
2. Subjects may refuse to have multiple swabs taken. Patients may refuse to give 5 samples.
Since the self-collected sites are unlikely to cause discomfort we expect that most
participants will agree to study participation. Even if many patients do not agree to
participate there are 700 patients per day presenting with symptoms which a large pool
of potential participants which will make it feasible to reach our goal. The
investigators may need to continue enrollment until there are 100 self-collected
COVID-19 + subjects if some subjects refuse additional tests.
3.2 Specific Aim 2. Evaluate the incidence of adverse events in a self-collected
mid-turbinate sample. According to the instructions for use (IFU), mid-turbinate swabs are
required to be collected under medical supervision,13 which the CDC reinforces. There have
been multiple studies that have demonstrated that mid-turbinate samples are effective for
detection of other respiratory illnesses.14-17 Since mid-turbinate collection may have higher
sensitivity than anterior nares or saliva testing, it is important to demonstrate that it can
be safely collected without clinical supervision. Although some patients may be able to
perform a mid-turbinate collection via a telehealth visit this would be a barrier to wide
scale-up. Thus, the investigators will allow patients to self-collect a mid-turbinate sample
with a collection swab. The swab will have an indicator line signaling the mean length to
reach the mid-turbinate region in adults (approximately 1 inch, or 2 cms). The healthcare
provider will then evaluate the patient for any adverse events related to the patient
self-collection, such as pain and/or bleeding. If the incidence of adverse events is absent
or very low (less than 5%) and the sensitivity of the mid-turbinate sample is superior to the
anterior nares, patients could be allowed to sample their own mid-turbinate region without
medical supervision. The proportion of participants experiencing each type of adverse event
will be estimated along with a corresponding 95% exact confidence interval.
4.0 Summary The Covid-19 pandemic has created a global crisis that is affecting all sectors
of society. To decrease the catastrophic economic and healthcare impacts of this virus, the
availability of safe, inexpensive, and reliable testing will be necessary. This project aims
to study the self-collection of a low-cost, rapid test (iAMP®) in three anatomic areas - the
mid-turbinate, the nares and saliva - that, if validated, can help make widespread testing a
real possibility. The secondary aim is to show that all of these areas can be safely
self-collected without the need for clinician supervision. Decreasing barriers to Covid-19
testing and processing will help to mitigate this crisis and allow for a return to normal
activities.
